Diagnosing and treating active myocarditis

Area of Science:

• Cardiology
• Immunology
• Virology

Background:

• Current treatments for dilated cardiomyopathy (DCM) are palliative, offering limited impact on disease progression and mortality.
• A subset of DCM cases may be caused by active myocarditis, suggesting a need for etiological treatments.
• Murine coxsackievirus B3 myocarditis models exhibit immunopathogenic similarities to human disease, indicating autoimmune processes.

Purpose of the Study:

• To investigate the potential role of active myocarditis as a cause of dilated cardiomyopathy.
• To evaluate the efficacy of immunosuppressive therapy in patients with active myocarditis.
• To determine the natural history of active myocarditis and its impact on DCM progression.

Main Methods:

• Utilized a murine coxsackievirus B3 myocarditis model to study immunopathogenic mechanisms.
• Conducted preliminary uncontrolled studies assessing clinical and histologic outcomes with immunosuppressive therapy in myocarditis patients.
• Initiated a multicenter study to enroll patients for evaluating immunosuppression efficacy and natural history.

Main Results:

• Preliminary studies suggest that immunosuppressive therapy may lead to clinical and histologic improvement in patients with myocarditis.
• A significant rate of spontaneous improvement in myocarditis patients was also observed.
• The murine model highlights persistent autoimmune reactivity post-viral clearance as a driver of myocyte damage in DCM.

Conclusions:

• Active myocarditis is a potential contributor to dilated cardiomyopathy in certain patients.
• Immunosuppressive therapy warrants further investigation as a potential treatment for DCM caused by active myocarditis.
• Further research, including the ongoing multicenter study, is crucial to establish definitive treatment strategies and understand the natural history of active myocarditis.